Vanguard Global Advisers’s Abeona Therapeutics ABEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$98.8K Buy
18,810
+202
+1% +$1.25K ﹤0.01% 2779
2026
Q2
$115K Hold
18,608
– – ﹤0.01% 2721
2026
Q1
$83.4K Buy
+18,608
New +$93K ﹤0.01% 2802

Other funds holding ABEO

Vanguard Global Advisers's ABEO Position: Q3 2026 in Review

Vanguard Global Advisers increased its Abeona Therapeutics (ABEO) stake by 1.1% in Q3 2026, buying an estimated $1.25K and bringing the position to 18,810 shares worth $98.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2779.

Vanguard Global Advisers first reported a position in ABEO in Q1 2026 and has held it in 3 quarters since. The position peaked at $115K in Q2 2026. 116 funds tracked by Wall St. Rank hold ABEO as of Q3 2026.

  • Vanguard Global Advisers held 18,810 shares of Abeona Therapeutics worth $98.8K as of Q3 2026.
  • Vanguard Global Advisers bought 202 Abeona Therapeutics shares in Q3 2026, an estimated $1.25K.
  • Abeona Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2779 holding.
  • Vanguard Global Advisers first reported a position in Abeona Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Abeona Therapeutics position peaked at $115K in Q2 2026.
  • 116 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.